Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

We assessed the association between baseline vitamin D and incident TB in a prospective cohort of 6,751 HIV-negative household contacts of TB patients enrolled between September 1, 2009, and August 29, 2012, in Lima, Peru.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis

Source: Article title.

Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis

Systematic review · PLoS Medicine · 2019

Original publication title

Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis

Omowunmi Aibana; Chuan-Chin Huang; Said Aboud; Alberto Arnedo-Pena; Mercedes C. Becerra; Juan Bautista Bellido-Blasco; Ramesh Bhosale; Roger Calderon; Silvia Chiang; Carmen Contreras; Ganmaa Davaasambuu; Wafaie W. Fawzi; Molly F. Franke; Jerome T. Galea; Daniel Garcia-Ferrer; Maria Gil-Fortuño; Barbará Gomila-Sard; Amita Gupta; Nikhil Gupte; Rabia Hussain; Jesus Iborra-Millet; Najeeha T. Iqbal; Jose Vicente Juan-Cerdán; Aarti Kinikar; Leonid Lecca; Vidya Mave; Noemi Meseguer-Ferrer; Grace Montepiedra; Ferdinand M. Mugusi; Olumuyiwa A. Owolabi; Julie Parsonnet; Freddy Roach-Poblete; Maria Angeles Romeu-García; Stephen A. Spector; Christopher R. Sudfeld; Mark W. Tenforde; Toyin O. Togun; Rosa Yataco; Zibiao Zhang; Megan B. Murray

© 2019 Aibana et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Our findings suggest vitamin D predicts TB disease risk in a dose-dependent manner and that the risk of TB disease is highest among HIV-positive individuals with severe vitamin D deficiency. Randomized control trials are needed to evaluate the possible role of vitamin D supplementation on reducing TB disease risk.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Few studies have evaluated the association between preexisting vitamin D deficiency and incident tuberculosis (TB). We assessed the impact of baseline vitamins D levels on TB disease risk.

Source: Background

Abstract: Methods and findings

We assessed the association between baseline vitamin D and incident TB in a prospective cohort of 6,751 HIV-negative household contacts of TB patients enrolled between September 1, 2009, and August 29, 2012, in Lima, Peru. We screened for TB disease at 2, 6, and 12 months after enrollment. We defined cases as household contacts who developed TB disease at least 15 days after enrollment of the index patient. For each case, we randomly selected four controls from among contacts who did not develop TB disease, matching on gender and year of age.

We also conducted a one-stage individual-participant data (IPD) meta-analysis searching PubMed and Embase to identify prospective studies of vitamin D and TB disease until June 8, 2019. We included studies that assessed vitamin D before TB diagnosis. In the primary analysis, we defined vitamin D deficiency as 25: (OH)D < 50 nmol/L, insufficiency as 50 to 75 nmol/L, and sufficiency as >75nmol/L. We estimated the association between baseline vitamin D status and incident TB using conditional logistic regression in the Lima cohort and generalized linear mixed models in the meta-analysis.

We further defined severe vitamin D deficiency as 25: (OH)D < 25 nmol/L and performed stratified analyses by HIV status in the IPD meta-analysis. In the Lima cohort, we analyzed 180 cases and 709 matched controls. The adjusted odds ratio (aOR) for TB risk among participants with baseline vitamin D deficiency compared to sufficient vitamin D was 1.63 (95% CI 0.75 to 3.52; p = 0.22). We included seven published studies in the meta-analysis and analyzed 3,544 participants. In the pooled analysis, the aOR was 1.48 (95% CI 1.04 to 2.10; p = 0.03).

The aOR for severe vitamin D deficiency was 2.05 (95% CI 0.87 to 4.87; p trend for decreasing 25: (OH)D levels from sufficient vitamin D to severe deficiency = 0.02). Among 1,576 HIV-positive patients, vitamin D deficiency conferred a 2-fold (aOR 2.18, 95% CI 1.22 to 3.90; p = 0.01) increased risk of TB, and the aOR for severe vitamin D deficiency compared to sufficient vitamin D was 4.28 (95% CI 0.85 to 21.45; p = 0.08). Our Lima cohort study is limited by the short duration of follow-up, and the IPD meta-analysis is limited by the number of possible confounding covariates available across all studies.

Source: Methods and findings

Abstract: Why was this study done?

  • Although multiple lines of evidence suggest that vitamin D may play a role in host susceptibility to tuberculosis (TB) disease, the impact of low vitamin D on the risk of developing TB disease has not yet been firmly established.

Source: Why was this study done?

Abstract: What did the researchers do and find?

  • We conducted a study in Lima, Peru, in which we measured serum 25: (OH)D levels in individuals at high risk for TB disease and followed them for development of TB over 1 year.

  • We pooled individual-level data from seven previously published prospective studies conducted worldwide and from our Lima cohort.

  • We found that individuals with low levels of vitamin D were at higher risk of future progression to TB disease.

Source: What did the researchers do and find?

Abstract: What do these findings mean?

  • These findings suggest that vitamin D deficiency is a risk factor for developing TB disease.

  • Randomized control trials are needed to determine whether vitamin D supplementation reduces risk of TB disease.

Source: What do these findings mean?

Abstract: Conclusion

Our findings suggest vitamin D predicts TB disease risk in a dose-dependent manner and that the risk of TB disease is highest among HIV-positive individuals with severe vitamin D deficiency. Randomized control trials are needed to evaluate the possible role of vitamin D supplementation on reducing TB disease risk.

Source: Conclusion
Authors’ abstract

Background

Few studies have evaluated the association between preexisting vitamin D deficiency and incident tuberculosis (TB). We assessed the impact of baseline vitamins D levels on TB disease risk.

Methods and findings

We assessed the association between baseline vitamin D and incident TB in a prospective cohort of 6,751 HIV-negative household contacts of TB patients enrolled between September 1, 2009, and August 29, 2012, in Lima, Peru. We screened for TB disease at 2, 6, and 12 months after enrollment. We defined cases as household contacts who developed TB disease at least 15 days after enrollment of the index patient. For each case, we randomly selected four controls from among contacts who did not develop TB disease, matching on gender and year of age.

We also conducted a one-stage individual-participant data (IPD) meta-analysis searching PubMed and Embase to identify prospective studies of vitamin D and TB disease until June 8, 2019. We included studies that assessed vitamin D before TB diagnosis. In the primary analysis, we defined vitamin D deficiency as 25: (OH)D < 50 nmol/L, insufficiency as 50 to 75 nmol/L, and sufficiency as >75nmol/L. We estimated the association between baseline vitamin D status and incident TB using conditional logistic regression in the Lima cohort and generalized linear mixed models in the meta-analysis.

We further defined severe vitamin D deficiency as 25: (OH)D < 25 nmol/L and performed stratified analyses by HIV status in the IPD meta-analysis. In the Lima cohort, we analyzed 180 cases and 709 matched controls. The adjusted odds ratio (aOR) for TB risk among participants with baseline vitamin D deficiency compared to sufficient vitamin D was 1.63 (95% CI 0.75 to 3.52; p = 0.22). We included seven published studies in the meta-analysis and analyzed 3,544 participants. In the pooled analysis, the aOR was 1.48 (95% CI 1.04 to 2.10; p = 0.03).

The aOR for severe vitamin D deficiency was 2.05 (95% CI 0.87 to 4.87; p trend for decreasing 25: (OH)D levels from sufficient vitamin D to severe deficiency = 0.02). Among 1,576 HIV-positive patients, vitamin D deficiency conferred a 2-fold (aOR 2.18, 95% CI 1.22 to 3.90; p = 0.01) increased risk of TB, and the aOR for severe vitamin D deficiency compared to sufficient vitamin D was 4.28 (95% CI 0.85 to 21.45; p = 0.08). Our Lima cohort study is limited by the short duration of follow-up, and the IPD meta-analysis is limited by the number of possible confounding covariates available across all studies.

Conclusion

Our findings suggest vitamin D predicts TB disease risk in a dose-dependent manner and that the risk of TB disease is highest among HIV-positive individuals with severe vitamin D deficiency. Randomized control trials are needed to evaluate the possible role of vitamin D supplementation on reducing TB disease risk.

Author summary

Why was this study done?

  • Although multiple lines of evidence suggest that vitamin D may play a role in host susceptibility to tuberculosis (TB) disease, the impact of low vitamin D on the risk of developing TB disease has not yet been firmly established.

What did the researchers do and find?

  • We conducted a study in Lima, Peru, in which we measured serum 25: (OH)D levels in individuals at high risk for TB disease and followed them for development of TB over 1 year.

  • We pooled individual-level data from seven previously published prospective studies conducted worldwide and from our Lima cohort.

  • We found that individuals with low levels of vitamin D were at higher risk of future progression to TB disease.

What do these findings mean?

  • These findings suggest that vitamin D deficiency is a risk factor for developing TB disease.

  • Randomized control trials are needed to determine whether vitamin D supplementation reduces risk of TB disease.

Publication and source details

Original title: Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis

Omowunmi Aibana; Chuan-Chin Huang; Said Aboud; Alberto Arnedo-Pena; Mercedes C. Becerra; Juan Bautista Bellido-Blasco; Ramesh Bhosale; Roger Calderon; Silvia Chiang; Carmen Contreras; Ganmaa Davaasambuu; Wafaie W. Fawzi; Molly F. Franke; Jerome T. Galea; Daniel Garcia-Ferrer; Maria Gil-Fortuño; Barbará Gomila-Sard; Amita Gupta; Nikhil Gupte; Rabia Hussain; Jesus Iborra-Millet; Najeeha T. Iqbal; Jose Vicente Juan-Cerdán; Aarti Kinikar; Leonid Lecca; Vidya Mave; Noemi Meseguer-Ferrer; Grace Montepiedra; Ferdinand M. Mugusi; Olumuyiwa A. Owolabi; Julie Parsonnet; Freddy Roach-Poblete; Maria Angeles Romeu-García; Stephen A. Spector; Christopher R. Sudfeld; Mark W. Tenforde; Toyin O. Togun; Rosa Yataco; Zibiao Zhang; Megan B. Murray

PLoS Medicine · 2019

The authors of this manuscript have the following competing interests: MBM is a member of the Editorial Board of PLOS Medicine. All other authors have declared no competing interests.

* E-mail: megan.murray.epi@gmail.com
© 2019 Aibana et al2019Aibana et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious DiseasesU19AI076217http://orcid.org/0000-0003-0443-1986Murray Megan B. http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious DiseasesU01AI057786http://orcid.org/0000-0003-0443-1986Murray Megan B. http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious DiseasesTBRU U19AI111224http://orcid.org/0000-0003-0443-1986Murray Megan B. http://dx.doi.org/10.13039/100000026National Institute on Drug AbuseT32DA013911http://orcid.org/0000-0003-0665-5393Aibana Omowunmi http://dx.doi.org/10.13039/100000025National Institute of Mental HealthR25MH083620http://orcid.org/0000-0003-0665-5393Aibana Omowunmi http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious DiseasesUM1AI068632http://orcid.org/0000-0001-7036-2718Gupta Amita http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious DiseasesUM1AI068616http://orcid.org/0000-0001-7036-2718Gupta Amita http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious DiseasesUM1AI106716http://orcid.org/0000-0001-7036-2718Gupta Amita http://dx.doi.org/10.13039/100000071National Institute of Child Health and Human DevelopmentN01-DK-9-001/HHSN267200800001Chttp://orcid.org/0000-0001-7036-2718Gupta Amita http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious DiseasesUM1AI069465http://orcid.org/0000-0001-7036-2718Gupta Amita http://dx.doi.org/10.13039/100000065National Institute of Neurological Disorders and Stroke5R01NS077874http://orcid.org/0000-0002-1882-4855Spector Stephen A. http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious DiseasesU01AI068636http://orcid.org/0000-0002-8702-8393Tenforde Mark W. http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious DiseasesU01AI069497http://orcid.org/0000-0001-7036-2718Gupta Amita http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious DiseasesR01AI080417http://orcid.org/0000-0001-7036-2718Gupta Amita http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious DiseasesUM1AI069465http://orcid.org/0000-0001-7036-2718Gupta Amita http://dx.doi.org/10.13039/100000002National Institutes of HealthF32AI140511http://orcid.org/0000-0002-8702-8393Tenforde Mark W. http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious DiseasesR01 AI45462http://orcid.org/0000-0001-8509-4517Mave Vidya http://dx.doi.org/10.13039/100000061Fogarty International CenterD43-TW0000http://orcid.org/0000-0001-8509-4517Mave Vidya http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious DiseasesU01 AI069497http://orcid.org/0000-0001-8509-4517Mave Vidya http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious DiseasesUM1 AI069465http://orcid.org/0000-0001-8509-4517Mave Vidya http://dx.doi.org/10.13039/100000071National Institute of Child Health and Human DevelopmentR01 HD32257Sudfeld Christopher R. National Commission on BiotechnologyPCST/NCB-AC3/2003Iqbal Najeeha T. http://dx.doi.org/10.13039/501100010221Higher Education Commision, PakistanHEC#20/796/ R&D/06Iqbal Najeeha T. http://dx.doi.org/10.13039/100000061Fogarty International CenterK01TW010829Chiang Silvia MBM acknowledges funding from the National Institute of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID) (U19AI076217, U01AI057786, TBRU U19AI111224; https://report.nih.gov/). OA acknowledges funding from the National Institute on Drug Abuse (NIDA) (T32DA013911); https://www.drugabuse.gov/international/research-funding-landing) and National Institute of Mental Health (NIMH) (R25MH083620; https://report.nih.gov/). AG, GM, and SAS acknowledge funding for the NWCS113 International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) study provided by National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under award numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC), and UM1AI106716 (IMPAACT LC), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH). Support of the sites was provided by NIAID and the NICHD International and Domestic Pediatric and Maternal HIV Clinical Trials Network (NICHD contract number N01-DK-9-001/HHSN267200800001C), NIAID (UM1AI069465 to AG), and NINDS (5R01NS077874 to SAS; https://report.nih.gov/). MWT and AG acknowledge the NWCS319 project was supported by Award Number U01AI068636 to the AIDS Clinical Trials Group from the National Institute of Allergy and Infectious Diseases and supported by National Institute of Mental Health (NIMH) and National Institute of Dental and Craniofacial Research (NIDCR). The work was also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (U01AI069497, R01AI080417, UM1AI069465 to AG). The parent trial A5175 was also supported in part by Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline. MWT also acknowledges funding from NIH (F32AI140511; https://report.nih.gov/). AG, VM, and NG acknowledge research reported in this publication was supported by Gilead Foundation (https://www.gilead.com/purpose/giving/gilead-foundation), Ujala Foundation (Newtown Square, PA, USA), and Wyncote Foundation (Philadelphia, PA, USA; https://www.gilead.com/purpose/giving/gilead-foundation). VM, NG, RB, AK, and AG acknowledge funding for the SWEN trial was supported by the NIAID (R01 AI45462), the NIH: Fogarty International Center Program of International Training Grants in Epidemiology Related to AIDS (D43-TW0000), the NIAID Byramjee Jeejeebhoy Medical College HIV Clinical Trials Unit (U01 AI069497), and the NIAID’s Baltimore-Washington-India Clinical Trials Unit (UM1 AI069465; https://report.nih.gov/). CRS acknowledges funding from the National Institute of Child Health and Human Development (R01 HD32257; https://report.nih.gov/). NTI acknowledges funding from the National Commission on Biotechnology (PCST/NCB-AC3/2003), the Higher Education Commission (HEC#20/796/ R&D/06; http://www.hec.gov.pk/english/pages/home.aspx), the International Research Support Initiative Program of the Higher Education Commission Government of Pakistan (http://www.hec.gov.pk/english/scholarshipsgrants/IRSIP/Pages/default.aspx), and the Bill and Melinda Gates Foundation (https://www.gatesfoundation.org/). SC acknowledges funding from the NIH Fogarty International Center (K01TW010829; https://report.nih.gov/). No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:30:20.275352+00:00

DOI: 10.1371/journal.pmed.1002907 · PMC6738590